Full Press Release Details
Oculus Innovative Sciences, Inc.
1129 N. McDowell Blvd.
Petaluma, California 94954
To the Shareholders of Oculus Innovative
In our annual letters to shareholders
in 2008 and 2009, we discussed the worst recession in the United States since the Great Depression and the resulting impact
on our business. In 2010, we discussed how our Company was turning the corner, focusing on partnering and growth opportunities
in an effort to push towards profitability.
2011 has been a year of growth
for our Company and I feel good about our future during the rest of 2012 and beyond. Here is a brief look back at the
highlights from our fiscal year ending March 31, 2012:
We believe one of the important future
challenges facing our Company is to design and conduct the necessary clinical trials needed to obtain "treatment of
infection" label claims. The seven FDA medical device clearances we have received to date do not allow us to market
our products for the treatment of infection and separately, to reduce the use of antibiotics. We hope to address this issue with
our new planned filings with FDA for the use of Microcyn in the surgical suite.
In the last two months, our stock price
has decreased which has had NASDAQ listing implications. We are working diligently to resolve these NASDAQ issues. We believe
our stock price is undervalued not just compared to our peers, but also because the market has not yet valued several of our
new partnerships and the robust R&D projects we are currently working on. Our challenge in the future is to better communicate
our strategy regarding these new products, and reduce the clinical and regulatory risks in the approval process, in an effort
to increase long term shareholder value.
Part of my job is to set the strategy
and course for the future, so here is a brief look forward.
We intend to continue to maximize our
Microcyn Technology opportunities in two ways: (a) to support our existing partners with new innovative and proprietary
products and (b) to develop new products for big, untapped markets. One untapped market that we are continuing to plan for
is in the surgical suite. Trauma and acute surgeries both rely heavily upon good old fashioned saline spiked with an
antibiotic. We believe our Microcyn Technology can replace many of those old, overused antibiotics, with better patient
outcomes and without concern over antibiotic resistance. Stayed tuned on this important market - we'll be communicating
soon about our strategy and plans. We believe we are on the right track and look forward to a great 2013.
our Annual Meeting of Stockholders will be held at 10:00 a.m., Eastern Daylight Time, on Tuesday, September 11, 2012,
at Marcum LLP, 750 3rd Avenue, 11th Floor, New York, NY 10017. Bob, Jim and I always enjoy the meeting, and
we hope you can join us this year. As Warren Buffet has said, the quality of our shareholders is reflected in the quality
of the questions we get. As such, if you are unable to attend and ask questions in person, please shoot us a note at:
Secretary, Oculus Innovative Sciences, Inc., 1129 N. McDowell Blvd., Petaluma, California 94954,
and we'll do our best to answer questions as quickly as we are able.
I hope you will join us at the Annual
Meeting and thank you for your continued support.
Chairman of the Board and Chief Executive Officer